Resources from the same session
LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
Presenter: Mariano Provencio Pulla
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1264MO - IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
Presenter: Nasser Altorki
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA58 - Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial
Presenter: Dongsheng Yue
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA59 - Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
Presenter: Martin Reck
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA57, 1264MO, LBA58 and LBA59
Presenter: Edward Garon
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
LBA61 - Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Presenter: Marina Garassino
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1292MO - A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A
Presenter: Ryo Ko
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA62 - Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
Presenter: Andrea Riccardo Filippi
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial
Presenter: Farastuk Bozorgmehr
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast